CHRONIC GVHD

Intersecting Aspects in Systemic and Ocular Disease

OCTOBER 22, 2016

UIC Department of Ophthalmology and Visual Sciences

VENUE: COM WEST TOWER, 2ND FLOOR, 1853 W. POLK STREET, CHICAGO, IL 60612
Message from the Department Head...

Dear Colleagues,

I welcome your participation in The Chronic GVHD: Intersecting Aspects in Systemic and Ocular Disease Meeting at the newly renovated state-of-the-art facilities of the College of Medicine (COM) Learning Center.

The University of Illinois COM boasts several thriving biomedical discovery programs in basic science and clinical departments. Our research goals are centered on fostering interdisciplinary research collaboration and translating our strengths in biomedical and behavioral discoveries and the University's strengths in technological innovations into clinical applications, including addressing unmet medical needs. A key initiative of the UI COM is to foster clinically relevant translational research by NIH funded clinician scientists. With the help of all the GVHD symposium participants, Dr. Sandeep Jain’s research on ocular GVHD is a prime example of the ongoing translational research at the Ophthalmology Department and College of Medicine.

This meeting will address a difficulty that is intrinsic in the area of dry eye and ocular surface disease due to chronic ocular GVHD - the difficulty in disseminating information and developing new management strategies in a fast-changing discipline (science and clinical treatment of ocular GVHD) where the stakeholders come from multiple disparate pools (clinician, clinical trainees and researchers in ophthalmology, hematology, oncology and immunology). The meeting will facilitate exchange of ideas across multiple clinical centers in the Chicago metropolitan region, and between the Chicago region and scientists and clinicians elsewhere in the country.

I look forward to seeing you at this interdisciplinary meeting on Chronic GVHD: Intersecting Aspects in Systemic and Ocular Disease.

Mark I. Rosenblatt, MD, PhD, MBA
Professor and Head
Department of Ophthalmology & Visual Sciences
Director, Corneal Regenerative Medicine Laboratory
University of Illinois at Chicago

Our Department is dedicated to developing innovative research and clinical programs which will impact the lives of patients with blinding and debilitating disease. The Chronic GVHD: Intersecting Aspects in Systemic and Ocular Disease Meeting and the NIH funded clinical trial in ocular GVHD reflect this commitment. We have recently established the ocular GVHD and Dry Eye Clinic and the Ophthalmic Clinical Trials and Translational Center in our Department, which provide services and infrastructure to these GVHD programs and numerous other clinical and translational programs.

Please join us on the University of Illinois at Chicago campus on October 22nd, 2016 for this exciting meeting.

Sandeep Jain, MD
Associate Professor
Director, Ocular GVHD & Dry Eye Clinic
Department of Ophthalmology & Visual Sciences
University of Illinois at Chicago
Principal Investigator NEI/NIH Grant R13 EY027189
“The Chicago Chronic GVHD Meeting”

Damiano Rondelli, MD
Michael Reese Professor of Hematology
Division Chief, Hematology/Oncology
Director of Blood & Marrow Transplant
Director, Stem Cell Transplantation Program
University of Illinois at Chicago

Funding for this conference was made possible (in part) by 1 R13 EY027189-01 from the National Eye Institute [Principal Investigator: Sandeep Jain, MD]. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
### SCHEDULE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:30 - 8:00am</td>
<td>Introductions</td>
<td>Welcome by Dean of UIC College of Medicine</td>
</tr>
<tr>
<td>8:00 - 8:05am</td>
<td>Program Overview by Meeting Directors</td>
<td>Sandeep Jain, MD Damiano Rondelli, MD</td>
</tr>
<tr>
<td>8:05 - 8:10am</td>
<td>Introductions</td>
<td>Dimitri Azar, MD MBA</td>
</tr>
<tr>
<td>8:10 - 12:30pm</td>
<td>Intersecting Basic Aspects – Session I</td>
<td>Moderators: Mark Rosenblatt, MD, PhD, MBA &amp; Damiano Rondelli, MD</td>
</tr>
<tr>
<td>8:10 - 8:40am</td>
<td>Chronic GVHD: NIH Classification and Beyond</td>
<td>Madan Jagasia, MBBS, MS</td>
</tr>
<tr>
<td>8:40 - 9:00am</td>
<td>Ocular GVHD: Diagnostic &amp; Classification Criteria</td>
<td>Yoko Ogawa, MD</td>
</tr>
<tr>
<td>9:00 - 9:30am</td>
<td>Chronic GVHD: Histopathological Characteristics</td>
<td>David E. Kleiner, MD, PhD</td>
</tr>
<tr>
<td>9:30 – 9:50am</td>
<td>Ocular GVHD: Histopathology &amp; Clinical Presentation</td>
<td>Stella Kim, MD</td>
</tr>
<tr>
<td>9:50 – 10:15am</td>
<td>Questions</td>
<td></td>
</tr>
<tr>
<td>10:15 - 10:30am</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:30 - 12:30pm</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>10:30 - 11:00am</td>
<td>Systemic GVHD: Pathophysiological Basis</td>
<td>Bruce Blazar, MD</td>
</tr>
<tr>
<td>11:00 - 11:20am</td>
<td>Ocular GVHD: Pathophysiological Basis</td>
<td>Victor Perez, MD</td>
</tr>
<tr>
<td>11:20 – 11:50pm</td>
<td>Outcomes Assessment in Chronic GVHD</td>
<td>Stephanie Lee, MD, PhD</td>
</tr>
<tr>
<td>11:50 – 12:10pm</td>
<td>Questions</td>
<td></td>
</tr>
<tr>
<td>12:10 – 1:30pm</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>1:30 – 3:30pm</td>
<td>Intersecting Clinical Aspects</td>
<td>Moderators: Ellen Shorter, OD &amp; Pritesh Patel, MD</td>
</tr>
<tr>
<td>1:30 – 1:55pm</td>
<td>New Therapies for Chronic GVHD</td>
<td>Steven Z. Pavletic, MD, MS</td>
</tr>
<tr>
<td>1:55 – 2:20pm</td>
<td>Medical Management of Ocular GVHD</td>
<td>Francisco Amparo, MD, MSc</td>
</tr>
<tr>
<td>2:20 – 2:35pm</td>
<td>Prosthetic Devices in Ocular GVHD</td>
<td>Deborah Jacobs, MD</td>
</tr>
<tr>
<td>2:35 – 2:50pm</td>
<td>Neutrophils in Chronic Systemic Inflammation</td>
<td>J. Edwin Blalock, PhD</td>
</tr>
<tr>
<td>2:50 – 3:05pm</td>
<td>Neutrophils and NETs in Chronic ocular GVHD</td>
<td>Sandeep Jain, MD</td>
</tr>
<tr>
<td>3:05 – 3:15pm</td>
<td>Neutrophils in Inflammation Associated Meibomian Gland Dropout</td>
<td>Daniel Saban, PhD</td>
</tr>
<tr>
<td>3:15 – 3:30pm</td>
<td>Questions</td>
<td></td>
</tr>
<tr>
<td>3:30 – 3:45pm</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>3:45 – 4:45pm</td>
<td>Chronic GVHD Management in the Chicago Area: Panel Discussion</td>
<td>Moderators: Damiano Rondelli, MD &amp; Sandeep Jain, MD</td>
</tr>
<tr>
<td>4:45 – 6:00pm</td>
<td>Invited Early Career Clinician Scientist and Researcher Presentations</td>
<td>Moderators: Cintia De Paiva, MD, PhD &amp; John Galvin, MD, MPH</td>
</tr>
<tr>
<td>4:45 – 4:55pm</td>
<td>Role of B cells in Chronic GVHD</td>
<td>Stefanie Sarantopoulos, MD, PhD</td>
</tr>
<tr>
<td>4:55 – 5:05pm</td>
<td>CD45RA+ Naive T Cell Depletion to Prevent GVHD</td>
<td>Marie Bleakley, MD, PhD, M.MSC</td>
</tr>
<tr>
<td>5:05 – 5:15pm</td>
<td>Vorinostat to prevent GVHD - Phase II Clinical Trial</td>
<td>Sung Won Choi, MD, MS</td>
</tr>
<tr>
<td>5:15 – 5:25pm</td>
<td>Lymphocyte trafficking in acute GVHD</td>
<td>Ran Reshef, MD, Msc</td>
</tr>
<tr>
<td>5:25 – 5:35pm</td>
<td>Mouse model of Sjögren syndrome – T-cell role</td>
<td>Scott M Lieberman, MD, PhD</td>
</tr>
<tr>
<td>5:35 – 5:45pm</td>
<td>Lacrimal Gland stem cell transplant for dry eye</td>
<td>Vinay Aakalu, MD, MPH</td>
</tr>
<tr>
<td>5:45 – 6:00pm</td>
<td>Closing Remarks: Sandeep Jain, MD</td>
<td></td>
</tr>
</tbody>
</table>
BRUCE BLAZAR, MD | University of Minnesota Regents Professor of Pediatrics

Bruce Blazar, MD is a Regents Professor of Pediatrics in the Division of Blood and Marrow Transplantation at the University of Minnesota. Dr. Blazar is a member of the National Academy of Medicine, Association of American Physicians, American Society of Clinical Investigation, Society of Pediatric Research, and fellow of the American Association for the Advancement of Sciences. He has served as past Chair of the National Institutes of Health Cancer Immunopathology and Immunotherapy Study Section, and as a past member of the Immune Tolerance Network Executive Committee, Food and Drug Administration Biological Response Modifiers Advisory Committee. Dr. Blazar is the past recipient of an NIH MERIT Award, Ernest Beutler Prize from the American Society of Hematology, and is the principal investigator of several NIH funded studies focusing on BMT immunological studies. Dr. Blazar is the author of more than 650 manuscripts, 600 of which were peer-reviewed publications.

STEVEN Z. PAVLetic, MD, MS | National Cancer Institute Professor and Senior Clinician of Microbiology & Immunology

Steven Z. Pavletic, MD, MS is a Senior Clinician at the National Cancer Institute, Center for Cancer Research, NIH, Bethesda Maryland. Until October 2002, Dr. Pavletic served as the director of the Allogeneic Stem Cell Transplantation Program at University of Nebraska Medical Center, Omaha. In 2002, Dr. Pavletic received an appointment at the National Cancer Institute (NCI). He is the Head of the Graft-versus-Host and Autoimmunity Section in the Experimental Transplantation and Immunology Branch. In October 2006, Dr. Pavletic received the NCI Director’s award for his achievements in developing national and international consensus guidelines for clinical trials in chronic GVHD. He directs the NIH chronic GVHD study group and spearheaded and chaired the 2005 and 2014 NIH chronic GVHD Consensus Conferences.

STEPHANIE LEE, MD, PhD | University of Washington Professor of Medicine

Stephanie Lee, MD, MPH is a Professor of Medicine at the University of Washington and Member at Fred Hutchinson Cancer Research Center. Dr. Lee’s research interests include outcomes and health services research, focusing on allogeneic hematopoietic cell transplantation. She has a special interest in studies of quality of life, costs, and late effects, particularly chronic graft-versus-host disease. Her research program is funded by the National Cancer Institute and the Office of Rare Diseases Research, and she has published more than 250 papers in her research field. Her clinical interests include all types of allogeneic hematopoietic cell transplants and long-term follow-up of survivors.

DAVID E. KLEINER, MD, PhD | National Cancer Institute Senior Research Physician

David Kleiner, MD, PhD is a Senior Research Physician at the National Cancer Institute. He is responsible for overseeing the clinical service component of the Laboratory of Pathology. The laboratory serves as the anatomic pathology service for the NIH Clinical Center, supplying surgical pathology, hepatopathology, autopsy, cytopathology, flow cytometry, ultrastructural pathology, and cytogenetic diagnostic services. These services include both routine diagnostic services and pathology support for the many clinical research protocols carried out at the NIH.

MADAN JAGASIA, MBBS, MS | Vanderbilt University Professor of Medicine

Madan Jagasia, MBBS, MS is Professor of Medicine, Chief of Section of Hematology-Stem Cell Transplant and the Director of Outpatient Transplant Program at the Vanderbilt-Ingram Cancer Center. He is the co-leader of Translational Research and Interventional Oncology (TRIO) research program at Vanderbilt-IngramCancer Center. He specializes in stem cell transplant for hematological malignancies (leukemia, lymphoma, Myeloma, MDS) and bone marrow failure disorders. His research interest is graft-versus-host disease, an immune complication after a donor stem cell transplant. He established the long term transplant clinic (LTTC) at Vanderbilt. Dr. Jagasia has authored and co-authored more than 100 research articles in peer reviewed-journals. He is a member of the GVHD and Leukemia working committees for the Center of International Blood and Marrow Transplant Center and the steering committee for the NIH 2015 Consensus Criteria for Chronic GVHD.

J. EDWIN BLALOCK, PHD | University of Alabama at Birmingham Professor of Medicine

J. Edwin Blalock, PhD is a Professor of Medicine, Pulmonary, Allergy, and Critical Care Medicine Division and Scientific Director, Lung Health Center at the University of Alabama at Birmingham School of Medicine. Dr. Blalock is internationally recognized for his research in neuroimmunology, rational drug design, as well as the role of inflammation in chronic lung diseases. He has published over 300 journal articles and book chapters and enjoyed uninterrupted funding for the past 39 years. Dr. Blalock has served on two NIH study sections, as well as study sections for the American Heart Association and the National Multiple Sclerosis Society.
Robert B. Levy, PhD is a Professor of Microbiology & Immunology at the University of Miami. In his research, he utilizes pre-clinical animal models to develop strategies to regulate immune responses necessary for the success of allogeneic and autologous hematopoietic stem cell transplants (HSCT). Professor Levy has authored more than 125 peer-reviewed research articles directed to understanding the immunology of HSCT and his efforts to employ cancer vaccines against hematologic diseases including leukemia and lymphoma. Upon joining the Dept. of Microbiology & Immunology, Dr. Levy became the Director of the Graduate Program for 19 yrs. and has received the George Paff Award voted by the University of Miami medical students as the outstanding teaching faculty member 6 times. He currently serves as an Associate Editor of the journals Biology of Blood and Bone Marrow Transplantation and Bone Marrow Research.

Victor Perez, MD is a Professor of Ophthalmology at the University of Miami’s Bascom Palmer Eye Institute. He graduated from the University of Puerto Rico School of Medicine and trained in the Ophthalmology residency program at the Massachusetts Eye and Ear Infirmary, Harvard Medical School followed by fellowships in Corneal and External Diseases and Uveitis at Harvard. He is a National Eye Institute funded clinician scientist. His research is focused on Innate and Adaptive Immunological Responses in High-Risk Corneal Transplantation and Anterior Segment Immunology. He was recently awarded an NEI R01 grant to study Immunological Aspects of Ocular GVHD.

Deborah Jacobs, MD is currently the Medical Director at BostonSight and Faculty at Massachusetts Eye & Ear Cornea Service. She graduated from Harvard Medical School and trained in the Ophthalmology residency program and fellowship in Cornea and External Disease at Massachusetts Eye and Ear Infirmary, Harvard Medical School. Her clinical interests include ocular surface disease, corneal ectasia, contact lens, and prosthetic replacement of the ocular surface ecosystem (PROSE).

Yoko Ogawa, MD is a clinician and researcher at the Keio University School of Medicine Tokyo, Japan. She has published extensively on pathophysiology and clinical manifestations of ocular GVHD and currently is leading the International Chronic Ocular Graft-Versus-Host Disease Consensus Group. She is the lead author on the paper proposing consensus group diagnostic criteria on chronic ocular GVHD.

Stella Kim, MD is currently the Joe M. Green Jr. Professor of Clinical Ophthalmology at University of Texas Health Medical School. Dr. Kim graduated from Harvard Medical School and trained in the Ophthalmology residency program at the Massachusetts Eye and Ear Infirmary, Harvard Medical School, followed by fellowship training in Corneal and External Diseases at the Moran Eye Center, University of Utah. She gained extensive experience in treating ocular GVHD patients at MD Anderson Cancer Center where she served as a faculty member for approximately 13 years. Dr. Kim is a member of the International Chronic Ocular Graft-Versus-Host Disease Consensus Group.

Francisco Amparo, MD is an ophthalmologist, scientist and technology innovator in the field of cornea and inflammatory diseases of the ocular surface. He is a Clinical Investigator at the Cornea Service, Massachusetts Eye and Ear Infirmary, and Scientific Associate in Ophthalmology at the Schepens Eye Research Institute, Harvard Medical School. Dr. Amparo spearheads multiple fronts studying ocular GVHD at the Harvard Department of Ophthalmology and is a member of the International Chronic Ocular GVHD Consensus Group.
INVITED EARLY CAREER CLINICIAN SCIENTISTS AND RESEARCHERS

**DANIEL SABAN, PHD | Duke University  Assistant Professor**

Daniel Saban, PhD is a cellular immunologist studying immune pathogeneses of ophthalmic diseases and vision loss. Dr. Saban is currently an Assistant Professor of Ophthalmology and Immunology at Duke University. He is the PI of an R01 funded program studying the Allergic Eye Disease (AED) model, and a faculty member on a T32 training grant from NIH/NIAID awarded to the Department of Immunology and a K12 from the NIH/NEI awarded to Department of Ophthalmology. He is also the director of the flow cytometry module funded by a P30 grant by the NIH/NEI. In addition, Dr. Saban serves as an Associate Editor of J Ocul Pharmacol Ther and is a grant reviewer for multiple national and international grant funding agencies. Dr. Saban’s research has been recognized through several important awards, such as the Eleanor and Miles Shore fellowship, Fight For Sight, and Research to Prevent Blindness.

**STEFANIE SARANTOPOULOS, MD, PHD | Duke University  Associate Professor**

Stefanie Sarantopoulos, MD, PHD is an Associate Professor in Medicine at Duke University in the Division of Hematological Malignancies and Stem Cell Therapies. Dr. Stefanie Sarantopoulos received her MD and PhD degrees from Boston University School of Medicine. She completed her fellowship in hematology and oncology at Dana-Farber Cancer Institute as an Instructor in Medicine at Harvard Medical School. She has authored or co-authored over 40 peer-reviewed publications and over 15 reviews, commentaries, and book chapters. Her laboratory at Duke studies the extrinsic and intrinsic mechanisms that drive B cell biology and pathobiology after stem cell transplantation. Dr. Sarantopoulos is also the PI of an investigator-initiated clinical trial studying the effects of an inhibitor of B Cell Receptor inhibitors in chronic GVHD. Her research aimed at diminishing toxicity and improving efficacy of stem cell transplantation is funded by NIH (NHLBI) R01 HL 129061-01) and The Leukemia and Lymphoma Society (LLS TRP).

**MARIE BLEAKLEY, MD, PHD, M.MSC | University of Washington  Associate Professor**

Marie Bleakley, MD, PhD, M.Msc is a pediatric oncologist with expertise in hematopoietic stem cell transplantation (HCT) to treat leukemia. Donor immune cells that are present in the allogeneic stem cell graft along with the hematopoietic stem cells are a major part of the curative power of transplantation, but can also cause serious side-effects known as Graft-Versus-Host-Disease (GVHD). Dr. Bleakley is developing ways to optimize the use of immune T cells in transplantation, and in cell therapies given after transplantation, to prevent and treat relapse of leukemia by promoting the advantageous Graft-Versus-Leukemia (GVL) effect while minimizing GVHD.

**SUNG WON CHOI, MD, PHD | University of Michigan  Associate Professor**

Sung Won Choi, MD, PhD received a B.S. from the University of Michigan, M.D. from Wayne State University, and M.S. in Clinical Research Design and Statistical Analysis from the University of Michigan. She completed her pediatric residency at New York University and fellowship training in pediatric hematology-oncology at Michigan. She then joined the Department of Pediatrics and Communicable Diseases in 2006. Dr. Sung Won Choi is currently studying how to better prevent and treat acute GVHD, and currently is investigating the role of histone deacetylase inhibition in GVHD prevention and translating exciting laboratory insights into a phase 2 clinical trial.

**RAN RESHEF, MD, MSC | Columbia University Medical Center  Associate Professor**

Ran Reshef, MD, MSc is the Director of Translational Research in the Blood and Marrow Transplantation (BMT) Program at Columbia University Medical Center. He is also an investigator at the Columbia Center for Translational Immunology and a Member of the Herbert Irving Comprehensive Cancer Center. Dr. Reshef’s lab studies the immunologic responses that determine the outcome of stem-cell transplantation. His lab pioneered the use of targeted agents that prevent donor cell migration into organs in order to reduce the development of graft-versus-host disease. In addition, the lab investigates new methods to optimize donor selection, and develops personalized approaches based on the genetic makeup of donors, recipients and tumors. His Research is funded by the National Cancer Institute, American Society of Clinical Oncology, Department of Defense and National Marrow Donor Program and he previously received awards from the American Society of Hematology and Leukemia & Lymphoma Society.

**SCOTT M. LIEBERMAN, MD, PHD | University of Iowa  Assistant Professor**

Scott M Lieberman, MD, PhD is a pediatric rheumatologist with a special interest in childhood Sjögren syndrome. His research laboratory focuses on understanding immune dysregulation in a mouse model of Sjögren syndrome with specific interest in T cell mechanisms driving lacrimal gland-specific autoimmunity. He received his MD & PhD from Albert Einstein College of Medicine and completed his Residency in Pediatrics and Fellowship in Pediatric Rheumatology at The Children’s Hospital of Philadelphia.
VINAY AAKALU, MD, MPH  |  University of Illinois at Chicago  |  Assistant Professor

Vinay Aakalu MD, MPH is a clinician-scientist and oculofacial plastic surgeon. His clinical interests include thyroid eye disease and ocular surface reconstruction. He directs the Lacrimal Cell Biology Laboratory and Illinois Center for Thyroid Eye Disease at the University of Illinois at Chicago. Dr. Aakalu is supported by the NEI through a K08 grant for his research on lacrimal gland biology, lacrimal gland gene expression and lacrimal gland regeneration. He also studies peptide based therapeutics for ocular surface disease.

BRIAN C. BETTS, MD  |  University of South Florida  |  Assistant Professor

Brian C. Betts, MD is an assistant professor in the Department of Blood and Marrow Transplantation at Moffitt Cancer Center. He received his Doctorate of Medicine at Eastern Virginia Medical School in 2004. He completed his internal medicine residency at the University of Minnesota in 2007, and served as chief resident from 2007-2008. He went on to complete his subspecialty training in hematology and medical oncology at Memorial Sloan Kettering Cancer Center in 2011. Dr. Betts studies how human T-cell signal transduction may be controlled to prevent harmful graft-versus-host disease (GVHD) and preserve beneficial graft-versus-leukemia (GVL) after allogeneic hematopoietic cell transplantation.

ALAN HANASH, MD, PHD  |  Memorial Sloan Kettering Cancer Center  |  Assistant Member

Alan Hanash, MD, PhD is an Assistant Member of Memorial Sloan Kettering and an Attending Physician on the Adult Bone Marrow Transplant Service in the Department of Medicine. Dr. Hanash's research focuses on the immunology of hematopoietic transplantation and immune-mediated mechanisms of tissue damage and regeneration. His clinical expertise is in Hematologic Malignancies, Bone Marrow Transplantation, Transplant Immunology, Prevention of GVHD and Cytokines.

CHRISTIAN CAPITINI, MD  |  University of Wisconsin  |  Assistant Professor

Christian Capitini, MD graduated with a Distinction in Research at the University of Rochester School of Medicine and Dentistry in 2002. He then completed a residency in Pediatrics at the University of Minnesota in 2005, where he was inducted into the Arnold P. Gold Foundation Humanism in Medicine Honor Society. Dr. Capitini then completed a fellowship in Pediatric Hematology/Oncology through the joint program of Johns Hopkins University/National Cancer Institute (NCI) in 2008. He also served as Chief Fellow in the last year of fellowship. After completing a postdoctoral research fellowship at the NCI, Dr. Capitini joined the faculty of the University of Wisconsin-Madison as an Assistant Professor in 2011.

CINTIA DE PAIVA, MD, PHD  |  Baylor College of Medicine  |  Assistant Professor

Cintia De Paiva, MD, PhD is currently an Assistant Clinical Professor of Ophthalmology at Baylor College of Medicine. She graduated from State University of Campinas, Brazil and trained in the Ophthalmology residency program and fellowship in Corneal and External Diseases at the same school. She has a long time interest in research involving dry eye and the ocular surface, including the crosstalk between epithelial and immune cells. Dr. de Paiva is the current President of the International Ocular Surface Society.

LADAN ESPANDAR, MD, MS  |  University of Pittsburgh  |  Assistant Professor

Ladan Espandar, MD, MS is an Assistant Professor in the Ophthalmology Department at the University of Pittsburgh. She specializes in cornea, external disease and refractive surgery. Her clinical specialization is in cataract procedures, Dry Eye Syndrome, limbal cell deficiency, and graft vs. host disease. Her lab focuses on adult stem cell biology specifically the anti-inflammatory property of adipose derived stem cells in re-establishment of limbal niche and the molecular mechanism(s) of adipose derived stem cells and limbal epithelial stem cell interactions in limbal stem cell microenvironment restoration.

CRAIG BYERSDORFER, MD, PHD  |  University of Pittsburgh  |  Assistant Professor

Craig Alan Byersdorfer, MD, PhD is a pediatric hematologist-oncologist at the Children’s Hospital of Pittsburgh. His research interest is focused on immune cell metabolism during the dynamic interplay of immune reconstitution and T cell activation following allogeneic stem cell transplantation (alloSCT). The goal of his lab is to define metabolic pathways up-regulated in lymphocytes following alloSCT, particularly in the T cells which cause graft-versus-host disease (GVHD).
PRITESH PATEL, MD | University of Illinois at Chicago  Assistant Professor of Clinical Medicine and Hematology/Oncology

Pritesh Patel, MD is an Assistant Professor in the Department of Hematology/Oncology at the University of Illinois at Chicago College of Medicine. His research focuses on methods to reduce the risk of disease relapse after bone marrow transplants. Currently, Dr. Patel is developing methods of predicting susceptibility of leukemia to radiation and chemotherapy based upon the genetics of the disease. In addition he is developing several clinical trials for pre-transplant treatment with the hope of increasing the effectiveness while at the same time decreasing side effects.

JAYESH MEHTA, MD | Northwestern University  Professor of Medicine

Jayesh Mehta, MD is the Director of the Hematopoietic Stem Cell Transplantation Program of the Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine. He is an attending physician at Northwestern Memorial Hospital. His research interests encompass hematopoietic stem cell transplantation, the use of adult stem cells for tissue repair, multiple myeloma, and opportunistic infections in immunocompromised patients. He has developed a number of novel conditioning regimens and supportive therapy to improve the outcome of allogeneic transplantation for hematologic malignancies, particularly multiple myeloma.

PATRICK STIFF, MD | Loyola University Medical Center  Professor of Medicine and Hematology/Oncology

Patrick Stiff, MD is a Professor of Medicine at Loyola University Medical Center and Director of the Cardinal Bernardin Cancer Center Hematology/Oncology Division. He graduated from Loyola University Chicago Stritch School of Medicine and completed his residency in internal medicine at the Cleveland Clinic Foundation, followed by fellowship training in Hematology and Medical Oncology at the Memorial Sloan - Kettering Cancer Center. Dr. Stiff’s clinical expertise is in Bone Marrow Transplantation, Non-Hodgkin’s Lymphoma, Ovarian Cancer and Leukemia.

JOHN MACIEJEWSKI, MD, PHD | Rush University Medical Center  Assistant Professor of Hematology/Oncology

John Maciejewski, MD, PhD is an Assistant Professor of Hematology and Interim Director, Section of Bone Marrow Transplant & Cell Therapy at Rush University Medical Center. Dr. Maciejewski’s clinical expertise is in Bone Marrow and Stem Cell Transplantation, Graft-Versus-Host Disease, Hodgkin and Non-Hodgkin Lymphoma, Multiple Myeloma, Myeloproliferative Neoplasms, and Acute and Chronic Leukemia. His research interests are in Stem Cell Transplantation, Graft-Versus-Host Disease, Multiple Myeloma, and Acute Leukemias.

ANDREW ARTZ, MD, MS | University of Chicago  Associate Professor of Medicine and Hematology/Oncology

Andrew Artz, MD, MS is an Associate Professor of Medicine at the University of Chicago and the Clinical Director of the Hematopoietic Cellular Therapy Program. Dr. Artz’s clinical and research interest focus is on improving outcomes for older adults with hematologic conditions. He has worked to advance novel prognostic markers for allogeneic transplant, particularly among older adults. Dr. Artz started the Transplant Optimization Program (TOP) for older adults at the University of Chicago to better measure health and optimize outcome among older adults. He has pursued the novel approach of haplo-cord transplant. He also has a Geriatric Anemia Clinic where he works to better understand anemia and advance treatments.

SURENDRA BASTI, MD | Northwestern University Feinberg School of Medicine  Professor of Ophthalmology

Surendra Basti, MD is a Professor of Ophthalmology at Northwestern University Feinberg School of Medicine. His areas of clinical and research interest include ocular surface disease and dry eye, pediatric and adult cataracts, keratoconus and external eye disease related to cancer medications. He has authored 65 publications in peer-reviewed ophthalmology journals. In 2007, Dr. Basti was named to the list of the “Best Doctors in America” and has been named to this list each year since. In 2008, he received the achievement award from the American Academy of Ophthalmology.
CHARLES BOUCHARD, MD | Loyola University Medical Center  Professor and Chairman, Ophthalmology

Charles Bouchard, MD is the Department Chair of Ophthalmology and a Professor of Ophthalmology at the Stritch School of Medicine Loyola University. His clinical expertise is in Dry Eye Syndrome, Ocular Surface Disease, Stem Cell Transplantation and Keratoconus. Dr. Bouchard’s areas research interests include corneal transplant, corneal immunology, ocular surface reconstruction, Keratoconus and Stevens-Johnson syndrome.

ASIM FAROOQ, MD, MPH | University of Chicago  Assistant Professor, Ophthalmology

Asim Farooq, MD, MPH is an assistant Professor at the University of Chicago. Dr. Farooq served as research assistant at Provena Mercy Center (Aurora) Heart Center; at Northwestern University in its Illinois Mathematics and Science Academy Mentorship Program; at UIUC Department of Medical Education; and in UIUC’s Dept of Ophthalmology Ocular Virology Laboratory with Dr. Deepak Shukla as a Research to Prevent Blindness Medical Student Research Fellow. He has been awarded research support from the Illinois Society for the Prevention of Blindness, the Midwest Eye-Bank’s Eye and Vision Research Program and from Research to Prevent Blindness. Dr. Farooq has contributed to the local community through various service organizations as tutor educational volunteer and also provided vision screening services to local elementary schools.

ANJALI TANNAN, MD | Rush University, NorthShore Health  Assistant Professor, Ophthalmology

Anjali Tannan, MD is an Assistant Professor at Rush University Medical Center. She grew up in Oshkosh, Wisconsin and obtained both her Bachelor of Science and her Medical Degree from the University of Wisconsin-Madison. She then completed her internship and ophthalmology residency at Rush University Medical Center. She went on to pursue a fellowship in Cornea, External Diseases and Refractive surgery at the Stein Eye Center, UCLA. She has an interest in corneal infections, refractive cataract surgery, and corneal transplants.

SURI DWARAKANATHAN, MD | Cook County Hospital  Attending Physician, Ophthalmology

Suri Dwarakanathan, MD is an Attending Physician and Residency Program Director at John Stroger Hospital of Cook County. He graduated from Albany Medical College and completed his residency at Cook County Hospital, followed by fellowship training in Ophthalmology at University of Texas Southwestern at Dallas. Dr. Dwarakanathan clinical and research interest is in corneal and ocular surface disease.

ALI DJALILIAN, MD | University of Illinois at Chicago  Associate Professor of Ophthalmology

Ali Djalilian, MD specializes in cornea, ocular surface diseases, and immunologic diseases of the cornea and anterior segment. He is a leading expert on ocular surface reconstruction and has developed innovations in the surgical techniques for limbal stem cell transplantation. He bridges his clinical experience with his basic science and translational research projects, which have been funded in part by the National Eye Institute/NIH, Department of Defense, and Research to Prevent Blindness.

MARK ROSENBLATT, MD, PHD
Professor and Head
Department of Ophthalmology & Visual Sciences
Director, Corneal Regenerative Medicine Laboratory
University of Illinois at Chicago

CINTA DE PAVIA, MD, MPH
Assistant Professor of Ophthalmology
Department of Ophthalmology
Baylor College of Medicine

JOHN GALVIN, MD, MPH
Instructor of Medicine
Hematology/Oncology and Microbiology/Immunology
Northwestern University Feinberg School of Medicine

SOLEDAD CORTINA, MD
Assistant Professor of Ophthalmology
Director, Comprehensive Ophthalmology
Director, Artificial Cornea Program
University of Illinois of Chicago
In the Dry Eye and ocular GVHD Clinic, we use state-of-the-art diagnostic equipment to assess the severity and type of dry eye. We use customized treatments to treat dry eye and ocular GVHD. The Dry Eye and ocular GVHD Clinic seamlessly connects with Dr. Jain’s Basic Science Laboratory that receives federal grants from The National Institutes of Health (NIH) and is equipped with advanced cell and molecular biology tools that allow discovery of new diagnostic tests and therapeutic targets. The clinic and the laboratory are also connected to the Ophthalmic Clinical Trials and Translational Center for running dry eye and ocular GVHD clinical trials.

We use state-of-the-art diagnostic equipment to assess the severity and type of dry eye. These include:

- Assessment of disease severity using symptom analysis tools
- Keratograph analysis of tear break-up time and ocular redness score
- Tear Osmolarity measurements
- LipiView imaging of meibomian glands and analysis of lipid layer thickness
- MMP-9 inflammatory protein detection in tear fluid using InflammaDry
- Slit lamp anterior segment photography
- Research tests are performed in Dr. Sandeep Jain’s laboratory. These include immunostaining of tear fluid cells, measurement tear fluid extracellular DNA, and analysis of chemokines/cytokines in the tear fluid.

We use customized treatments to treat dry eye and ocular GVHD. In addition to standard treatments, these include:

- Compounded Methylprednisone eye drops
- Compounded Cyclosporine 1% and Tacrolimus eye drops
- Serum Tears and Platelet rich plasma tears
- PROSE scleral contact lenses
- PROKERA biologic corneal bandage devices

Clinic Information
For Appointments
Phone: (312) 996-8937
Text Message: (312) 918-0900
Email Christine Mun: mun2@uic.edu

Clinic Address
Illinois Eye and Ear Infirmary
1855 W. Taylor Street
Chicago, IL 60612

http://eyecare.uic.edu/clinics/DryEyeandOcularGVHDClinic.shtml
ONGOING OCULAR GVHD CLINICAL TRIALS

- A Prospective Study to Identify Bio-Markers that Predict Onset and Progression of ocular Graft-versus-Host Disease in Patients who receive Allogeneic Hematopoietic Stem Cell Transplant.
- A Phase I/II Randomized Placebo-Controlled, Double-Blind, Single-Center, Tolerability And Preliminary Efficacy Study Of Recombinant Human Deoxyribonuclease (rhDNase) Eye Drops In Patients With Dry Eye Disease.
- A Phase I/II Open-Label, Single-Center, Tolerability And Preliminary Efficacy Study of use of Brimonidine Eye Drops for Treatment of ocular Graft-versus-Host Disease (oGVHD).

Principal Investigator: Sandeep Jain, MD
Funding Agency: NEI/NIH R01 EY024966, Research to Prevent Blindness
Location: Ophthalmic Clinical Trials and Translational Center
Contact: 312-918-0900 or mun2@uic.edu

OPHTHALMIC CLINICAL TRIALS AND TRANSLATIONAL CENTER

The Ophthalmic Clinical Trials and Translational Center was established to provide services that evaluate preventative, therapeutic, and diagnostic interventions in ophthalmic diseases. Located on the second floor of the Illinois Eye and Ear Infirmary, the mission of the center is to design and run clinical trials and translational studies with world class academic ophthalmologists and federal and industry sponsors.

CORES:

Clinical Trials Core:
Certified ophthalmic examination lanes
Patient identification and recruitment strategies
IRB preparation and submission
Budget and contract negotiations
Specialized diagnostic equipment for research evaluation

Translational Research Core:
Intellectual property and commercialization consulting
Regulatory and oversight support to first in human studies

Data and statistics Core:
Epidemiological and biostatistical design and analyses spanning the entire biomedical research spectrum
Statistical programming involving data management, design/construction of databases and analyses

The Ophthalmic Clinical Trials and Translational Center also provides resources for the National Eye Institute Core Grant (NEI P30 EY001792) for vision research, by providing state-of-the-art clinical research equipment and technical expertise that is essential for the rapid advancement of vision science research and its sophisticated demands.

For more information please contact: Joelle Hallak, PhD, (312)996-0157, joelle@uic.edu
Webpage: ophthalmicct.uic.edu

Joelle Hallak, PhD
Executive Director

Clinical Research Coordinators:
Joe Baker
Roxana Ng
Jie (Jessica) Sun
Lauren Talasnik
ABOUT THE CHRONIC GVHD MEETING

Chronic GVHD is an extraordinarily complex disease in terms of pathophysiology and practical management that demands a multidisciplinary approach. Most of the management falls within the realm of internal medicine. Yet one of the most important manifestations of chronic GVHD is ophthalmological (severe dry eye disease), and ophthalmologists are separated from internal medicine by numerous barriers. This meeting is devoted to the intersection between ophthalmologist and hematologists/oncologists working in the areas of chronic GVHD and dry eye/ocular surface disease. By bringing together clinicians and scientists from different disciplines, including nationally recognized experts, this meeting will lower this barrier and promote interdisciplinary research and education and facilitate improvements in the management of patients with chronic ocular GVHD.

An important goal of this meeting is to provide a highly interactive, interdisciplinary forum for scientific exchange and collaboration amongst junior and senior scientists in the fields of hematology/oncology and ophthalmology.

Date of Meeting: Saturday, October 22nd, 2016

Location of Meeting:
The Learning Center, 2nd floor Room 227
UIC College of Medicine West Tower
1853 W. Polk Street
Chicago

Parking for Meeting:
Wood Street Parking Structure
Corner of Wood & Fillmore
1100 S Wood St
Chicago

Contact information:
Call (312) 996-6590
Call/Text: (312) 918-0900
Email: mun2@uic.edu

Online Registration Website:
www.signmeup.com/115509

Registration Fee: None